Getinge AB ( (GNGBY) ) has released its Q3 earnings. Here is a breakdown of the information Getinge AB presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Getinge AB is a global leader in medical technology, providing innovative solutions for healthcare and life sciences, with a focus on acute care therapies, life sciences, and surgical workflows. In its latest earnings report for Q3 2025, Getinge AB showcased significant organic growth in net sales and improved profitability despite geopolitical challenges. The company reported a 9.5% increase in organic net sales and a 4.7% rise in order intake, with notable performances in Acute Care Therapies and Life Science sectors. Adjusted EBITA margins improved across all business areas, driven by successful price adjustments and cost efficiency measures. Looking ahead, Getinge remains optimistic about its strategic positioning and continues to focus on expanding its market presence while navigating geopolitical headwinds.